Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biotechnology entities : Bristol-myers squibb company save search
Envisagenics Announces Research Collaboration with Bristol Myers Squibb
Published: 2022-11-29 (Crawled : 14:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.42%
H: 0.38%
C: 0.28%
research collaboration
Intensity Therapeutics' INT230-6 Data will be presented at the 2022 Society for Immunotherapy of Cancer Meeting
Published: 2022-11-11 (Crawled : 13:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -1.61%
H: 0.45%
C: -2.74%
int230 immunotherapy meeting cancer
BioSpace Movers & Shakers, April 1
Published: 2022-04-01 (Crawled : 15:00) - biospace.com/
RCOR | $3.2 0.0%
|
|
| O: 0.0%
H: 3.19%
C: -4.01%
WMT | News | $59.09 -1.75% -0.02% 18M
|
Retail Trade
|
| O: 0.5%
H: 1.08%
C: 0.9%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.64%
H: 0.6%
C: 0.57%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: -1.39%
H: 0.0%
C: 0.0%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.22%
H: 1.01%
C: 0.86%
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: 0.41%
H: 0.11%
C: -0.22%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
NVAX | $4.205 3.32% 3.21% 3.6M
|
Health Technology
|
| O: -0.48%
H: 4.07%
C: 1.39%
NKTX | $7.55 2.17% 2.12% 710K
|
Health Technology
|
| O: -1.23%
H: 4.98%
C: 1.78%
ALEC | $5.33 3.1% 3.0% 550K
|
Health Technology
|
| O: -0.21%
H: 2.39%
C: -1.05%
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
Published: 2021-12-10 (Crawled : 14:30) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
int230 symposium therapeutics therapy results cancer breast cancer metastatic breast cancer
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
Published: 2021-09-16 (Crawled : 09:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.41%
H: 1.11%
C: 0.76%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.23%
H: 0.31%
C: -1.02%
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: 0.0%
H: 0.83%
C: 0.34%
renal cell carcinoma
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.